Oprozomib (ONX 0912, PR-047) is an orally bioavailable inhibitor for CT-L activity of20S proteasomeβ5/LMP7 withIC50of 36 nM/82 nM. Phase 1/2. In vitro
The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis.
In vivo
Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models . Cell Data